The company's PFA and TAVR technologies both played key roles in the successful second quarter. In addition, Medtronic expects its place in the renal denervation market to make a major impact going forward. The company's PFA and TAVR technologies both played key roles in the successful second quarter. In addition, Medtronic expects its place in the renal denervation market to make a major impact going forward. | | |
|
Much more research is still required, but a new meta-analysis in Stroke suggests these medications may provide valuable stroke prevention. Much more research is still required, but a new meta-analysis in Stroke suggests these medications may provide valuable stroke prevention. | | |
|
No other heart or transplant services at the nonprofit hospital should be impacted by this temporary shift in care. No other heart or transplant services at the nonprofit hospital should be impacted by this temporary shift in care. | | |
|
The collaboration allows providers to order diagnostic tests and then receive results directly in Epic. The collaboration allows providers to order diagnostic tests and then receive results directly in Epic. | | |
|
|
Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call? Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call? | | |
|
A clinical trial focused on patients with HFpEF is expected to be completed by July 2026. A clinical trial focused on patients with HFpEF is expected to be completed by July 2026. | | |
|
According to Hexoskin, the newly cleared technology offers significant value for hospitals and health systems as well as researchers conducting clinical trials. According to Hexoskin, the newly cleared technology offers significant value for hospitals and health systems as well as researchers conducting clinical trials. | | |
|
The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy. The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy. | | |
|
|
The new patch is implanted through a tiny incision and held in place with a biocompatible adhesive. It then helps the heart recover over time, replacing dead tissue that would typically never be able to regenerate. The new patch is implanted through a tiny incision and held in place with a biocompatible adhesive. It then helps the heart recover over time, replacing dead tissue that would typically never be able to regenerate. | | |
|
As one may expect, patient satisfaction was considerably higher for individuals who did not have to fast for a minimum of six hours prior to treatment. There were no other significant differences. As one may expect, patient satisfaction was considerably higher for individuals who did not have to fast for a minimum of six hours prior to treatment. There were no other significant differences. | | |
|
A system-wide initiative in Sweden helped hospitals reduce readmission rates and shorten lengths of stay. When it came to heart failure patients specifically, however, the changes barely made an impact. A system-wide initiative in Sweden helped hospitals reduce readmission rates and shorten lengths of stay. When it came to heart failure patients specifically, however, the changes barely made an impact. | | |
|
|
One of the AI haves feels the pain of the AI have-nots. His discomfort is especially pronounced when he thinks about how hard it must be for financial strugglers to keep up with regulations and rumors of regulations to come. One of the AI haves feels the pain of the AI have-nots. His discomfort is especially pronounced when he thinks about how hard it must be for financial strugglers to keep up with regulations and rumors of regulations to come. | | |
|
A new analysis suggests approximately 1 out of every 10 patients presenting to the ED will complete a head CT during their visit. A new analysis suggests approximately 1 out of every 10 patients presenting to the ED will complete a head CT during their visit. | | |
|
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](https://cardiovascularbusiness.com/sites/default/files/styles/media_thumbnail/public/2024-09/istock-1209664264.jpg?itok=d9hdApI9)
